drugset / Trial / NCT00610103
Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when administered as a subcutaneous injection at the individualized maintenance dose level in an OFF state in Parkinson's disease patients with motor response complications on levodopa therapy.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apomorphine | Unknown | 1 mg | Subcutaneous |
| Comparator | Apomorphine | Unknown | 2 mg | Subcutaneous |
| Comparator | Apomorphine | Unknown | 3 mg | Subcutaneous |
| Comparator | Apomorphine | Unknown | 4 mg | Subcutaneous |
| Comparator | Apomorphine | Unknown | 5 mg | Subcutaneous |
| Comparator | Apomorphine | Unknown | 6 mg | Subcutaneous |